Motor deficits associated with Huntington's disease occur in the absence of striatal degeneration in BACHD transgenic mice

Human Molecular Genetics

Volumn 25, Issue 9, 2016, Pages 1780-1791

  Mantovani, Susanna ^a,b   Gordon, Richard ^a   Li, Rui ^a   Christie, Daniel C ^a   Kumar, Vinod ^a   Woodruff, Trent M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Wesley Research Institute   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; HUNTINGTIN; MUTANT PROTEIN; PHOSPHOPROTEIN DARPP 32; PROTEIN IBA1; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACHD MOUSE; BALANCE IMPAIRMENT; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN CORTEX; BRAIN NERVE CELL; BRAIN SIZE; C57BL 6 MOUSE; COGNITIVE FUNCTION TEST; CONTROLLED STUDY; DEPRESSION; FEMALE; GAIT; GLIOSIS; GRIP STRENGTH; HUNTINGTON CHOREA; LIFESPAN; MALE; MEMBRANE DAMAGE; MOTOR DYSFUNCTION; MOTOR FUNCTION TEST; MOUSE; MUSCLE STRENGTH; NERVE CELL NECROSIS; NEUROPATHOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; STRIATONIGRAL DEGENERATION; STRIDE LENGTH; TRANSGENIC MOUSE; VALIDATION STUDY; WEIGHT GAIN; WILD TYPE MOUSE; ANIMAL; ANIMAL BEHAVIOR; BRAIN; C57BL MOUSE; COGNITIVE DEFECT; CORPUS STRIATUM; DISEASE MODEL; HUMAN; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; BEHAVIOR, ANIMAL; BLOOD-BRAIN BARRIER; BRAIN; COGNITION DISORDERS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY;

EID: 84991392281     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddw050     Document Type: Article

References (61)

1. Moller, T. (2010) Neuroinflammation in Huntington's disease. J. Neural Transm., 117, 1001-1008.
2. Ross, C.A. and Tabrizi, S.J. (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol., 10, 83-98.
3. Group, T.H.s.D.C.R. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell, 72, 971-983.
4. Pouladi, M.A., Morton, A.J. and Hayden, M.R. (2013) Choosing an animal model for the study of Huntington's disease. Nat. Rev. Neurosci., 14, 708-721.
5. Lee, C.Y., Cantle, J.P. and Yang, X.W. (2013) Genetic manipulations of mutant huntingtin in mice: new insights into Huntington's disease pathogenesis. FEBS J., 280, 4382-4394.
6. Gray, M., Shirasaki, D.I., Cepeda, C., Andre, V.M., Wilburn, B., Lu, X.H., Tao, J., Yamazaki, I., Li, S.H., Sun, Y.E. et al. (2008) Fulllength human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J. Neurosci., 28, 6182-6195.
7. Dorsman, J.C., Bremmer-Bout, M., Pepers, B., vanOmmen, G.J. and Den Dunnen, J.T. (2002) Interruption of perfect CAG repeats by CAA triplets improves the stability of glutamine-encoding repeat sequences. Biotechniques, 33, 976-978.
8. William Yang, X. and Gray, M. (2011) In Lo, D.C. and Hughes, R.E. (eds), Neurobiology of Huntington's Disease: Applications to Drug Discovery, Boca Raton, FL, CRC Press/Taylor & Francis, Chapter 7.
9. Menalled, L., El-Khodor, B.F., Patry, M., Suarez-Farinas, M., Orenstein, S.J., Zahasky, B., Leahy, C., Wheeler, V., Yang, X.W., MacDonald, M. et al. (2009) Systematic behavioral evaluation of Huntington's disease transgenic and knock-in mouse models. Neurobiol. Dis., 35, 319-336.
10. Van Raamsdonk, J.M., Gibson, W.T., Pearson, J., Murphy, Z., Lu, G., Leavitt, B.R. and Hayden, M.R. (2006) Body weight is modulated by levels of full-length huntingtin. Hum. Mol. Genet., 15, 1513-1523.
11. Kudwa, A.E., Menalled, L.B., Oakeshott, S., Murphy, C., Mushlin, R., Fitzpatrick, J., Miller, S.F., McConnell, K., Port, R., Torello, J. et al. (2013) Increased body weight of the BAC HD transgenic mouse model of Huntington's disease accounts for some but not all of the observed HD-like motor deficits. PLoS Curr., 5, doi: 10.1371/currents.hd.0ab4f3645aff523c56ecc8ccbe41a198.
12. Spampanato, J., Gu, X., Yang, X.W. and Mody, I. (2008) Progressive synaptic pathology of motor cortical neurons in a BAC transgenic mouse model of Huntington's disease. Neuroscience, 157, 606-620.
13. Pouladi, M.A., Stanek, L.M., Xie, Y., Franciosi, S., Southwell, A.L., Deng, Y., Butland, S., Zhang, W., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet., 21, 2219-2232.
14. Abada, Y.S., Schreiber, R. and Ellenbroek, B. (2013) Motor, emotional and cognitive deficits in adult BACHD mice: a model for Huntington's disease. Behav. Brain Res., 238, 243-251.
15. Gafni, J., Papanikolaou, T., Degiacomo, F., Holcomb, J., Chen, S., Menalled, L., Kudwa, A., Fitzpatrick, J., Miller, S., Ramboz, S. et al. (2012) Caspase-6 activity in a BACHD mouse modulates steady-state levels of mutant huntingtin protein but is not necessary for production of a 586 amino acid proteolytic fragment. J. Neurosci., 32, 7454-7465.
16. Kordasiewicz, H.B., Stanek, L.M., Wancewicz, E.V., Mazur, C., McAlonis, M.M., Pytel, K.A., Artates, J.W., Weiss, A., Cheng, S.H., Shihabuddin, L.S. et al. (2012) Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron, 74, 1031-1044.
17. Aharony, I., Ehrnhoefer, D.E., Shruster, A., Qiu, X., Franciosi, S., Hayden, M.R. and Offen, D. (2015) A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Hum. Mol. Genet., 24, 2604-2614.
18. Ko, J., Ou, S. and Patterson, P.H. (2001) New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins. Brain Res. Bull., 56, 319-329.
19. Paulsen, J.S., Nehl, C., Hoth, K.F., Kanz, J.E., Benjamin, M., Conybeare, R., McDowell, B. and Turner, B. (2005) Depression and stages of Huntington's disease. J. Neuropsychiatry Clin. Neurosci., 17, 496-502.
20. Der-Avakian, A. and Markou, A. (2012) The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci., 35, 68-77.
21. Porsolt, R.D., Bertin, A. and Jalfre, M. (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther., 229, 327-336.
22. Carri, A.D., Onorati, M., Lelos, M.J., Castiglioni, V., Faedo, A., Menon, R., Camnasio, S., Vuono, R., Spaiardi, P., Talpo, F. et al. (2013) Developmentally coordinated extrinsic signals drive human pluripotent stem cell differentiation toward authentic DARPP-32+ medium-sized spiny neurons. Development, 140, 301-312.
23. Ouimet, C.C., Miller, P.E., Hemmings, H.C. Jr., Walaas, S.I. and Greengard, P. (1984) DARPP-32, a dopamine-and adenosine 3':5'-monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. J. Neurosci., 4, 111-124.
24. Ouimet, C.C., Langley-Gullion, K.C. and Greengard, P. (1998) Quantitative immunocytochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res., 808, 8-12.
25. Desplats, P.A., Kass, K.E., Gilmartin, T., Stanwood, G.D., Woodward, E.L., Head, S.R., Sutcliffe, J.G. and Thomas, E.A. (2006) Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J. Neurochem., 96, 743-757.
26. Rubio, I., Rodriguez-Navarro, J.A., Tomas-Zapico, C., Ruiz, C., Casarejos, M.J., Perucho, J., Gomez, A., Rodal, I., Lucas, J.J., Mena, M.A. et al. (2009) Effects of partial suppression of parkin on huntingtin mutant R6/1 mice. Brain Res., 1281, 91-100.
27. van Dellen, A., Welch, J., Dixon, R.M., Cordery, P., York, D., Styles, P., Blakemore, C. and Hannan, A.J. (2000) N-Acetylaspartate and DARPP-32 levels decrease in the corpus striatum of Huntington's disease mice. Neuroreport, 11, 3751-3757.
28. Bibb, J.A., Yan, Z., Svenningsson, P., Snyder, G.L., Pieribone, V.A., Horiuchi, A., Nairn, A.C., Messer, A. and Greengard, P. (2000) Severe deficiencies in dopamine signaling in presymptomatic Huntington's disease mice. Proc. Natl Acad. Sci. USA, 97, 6809-6814.
29. Luthi-Carter, R., Strand, A., Peters, N.L., Solano, S.M., Hollingsworth, Z.R., Menon, A.S., Frey, A.S., Spektor, B.S., Penney, E.B., Schilling, G. et al. (2000) Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum. Mol. Genet., 9, 1259-1271.
30. Metzler, M., Gan, L., Mazarei, G., Graham, R.K., Liu, L., Bissada, N., Lu, G., Leavitt, B.R. and Hayden, M.R. (2010) Phosphorylation of huntingtin at Ser421 in YAC128 neurons is associated with protection of YAC128 neurons fromNMDA-mediated excitotoxicity and is modulated by PP1 and PP2A. J. Neurosci., 30, 14318-14329.
31. Lin, C.Y., Hsu, Y.H., Lin, M.H., Yang, T.H., Chen, H.M., Chen, Y.C., Hsiao, H.Y., Chen, C.C., Chern, Y. and Chang, C. (2013) Neurovascular abnormalities in humans and mice with Huntington's disease. Exp. Neurol., 250C, 20-30.
32. Li, J.Y., Popovic, N. and Brundin, P. (2005) The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. NeuroRx, 2, 447-464.
33. Ferrante, R.J. (2009) Mouse models of Huntington's disease and methodological considerations for therapeutic trials. Biochim. Biophys. Acta, 1792, 506-520.
34. Rocher, A.B., Gubellini, P., Merienne, N., Boussicault, L., Petit, F., Gipchtein, P., Jan, C., Hantraye, P., Brouillet, E. and Bonvento, G. (2016) Synaptic scaling up in medium spiny neurons of aged BACHD mice: a slow-progression model of Huntington's disease. Neurobiol. Dis., 86, 131-139.
35. Ehrnhoefer, D.E., Butland, S.L., Pouladi, M.A. and Hayden, M.R. (2009) Mouse models of Huntington disease: variations on a theme. Dis. Model. Mech., 2, 123-129.
36. Bates, G.P., Mangiarini, L., Mahal, A. and Davies, S.W. (1997) Transgenic models of Huntington's disease. Hum. Mol. Genet., 6, 1633-1637.
37. Simmons, D.A., Belichenko, N.P., Yang, T., Condon, C., Monbureau, M., Shamloo, M., Jing, D., Massa, S.M. and Longo, F.M. (2013) A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease. J. Neurosci., 33, 18712-18727.
38. Schroeder, A.M., Loh, D.H., Jordan, M.C., Roos, K.P. and Colwell, C.S. (2011) Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease. PLoS Curr., 3, RRN1266.
39. Baldo, B., Cheong, R.Y. and Petersen, A. (2014) Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease. PLoS One, 9, e107691.
40. Boussicault, L., Herard, A.S., Calingasan, N., Petit, F., Malgorn, C., Merienne, N., Jan, C., Gaillard, M.C., Lerchundi, R., Barros, L.F. et al. (2014) Impaired brain energy metabolism in the BACHD mouse model of Huntington's disease: critical role of astrocyte-neuron interactions. J. Cereb. Blood Flow Metab., 34, 1500-1510.
41. Lee, W., Reyes, R.C., Gottipati, M.K., Lewis, K., Lesort, M., Parpura, V. and Gray, M. (2013) Enhanced Ca(2+)-dependent glutamate release from astrocytes of the BACHD Huntington's disease mouse model. Neurobiol. Dis., 58, 192-199.
42. Miller, S., Hill Della Puppa, G., Reidling, J., Marcora, E., Thompson, L.M. andTreanor, J. (2014) Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease. J. Huntingtons Dis., 3, 333-341.
43. Vonsattel, J.P. and DiFiglia, M. (1998) Huntington disease. J. Neuropathol. Exp. Neurol., 57, 369-384.
44. Jeyasingham, R.A., Baird, A.L., Meldrum, A. and Dunnett, S.B. (2001) Differential effects of unilateral striatal and nigrostriatal lesions on grip strength, skilled paw reaching and druginduced rotation in the rat. Brain Res. Bull., 55, 541-548.
45. Lundh, S.H., Soylu, R. and Petersen, A. (2012) Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse. PLoS One, 7, e51168.
46. Nardo, G., Iennaco, R., Fusi, N., Heath, P.R., Marino, M., Trolese, M.C., Ferraiuolo, L., Lawrence, N., Shaw, P.J. and Bendotti, C. (2013) Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain, 136, 3305-3332.
47. Antony, P.M., Diederich, N.J. and Balling, R. (2011) Parkinson's disease mouse models in translational research. Mamm. Genome, 22, 401-419.
48. Hsiao, K.K., Borchelt, D.R., Olson, K., Johannsdottir, R., Kitt, C., Yunis, W., Xu, S., Eckman, C., Younkin, S., Price, D. et al. (1995) Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron, 15, 1203-1218.
49. Chang, B., Hawes, N.L., Hurd, R.E., Davisson, M.T., Nusinowitz, S. and Heckenlively, J.R. (2002) Retinal degeneration mutants in the mouse. Vision Res., 42, 517-525.
50. Mineur, Y.S. and Crusio, W.E. (2002) Behavioral and neuroanatomical characterization of FVB/N inbred mice. Brain Res. Bull., 57, 41-47.
51. Gimsa, U., Kanitz, E., Otten, W. and Ibrahim, S.M. (2009) Behavior and stress reactivity in mouse strains with mitochondrial DNA variations. Ann. N. Y. Acad. Sci., 1153, 131-138.
52. Sapp, E., Kegel, K.B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P.G., Vonsattel, J.P. and DiFiglia, M. (2001) Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol., 60, 161-172.
53. Block, M.L., Zecca, L. and Hong, J.S. (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci., 8, 57-69.
54. Bjorkqvist, M., Wild, E.J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R.V., Benn, C.L., Soulet, D. et al. (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J. Exp. Med., 205, 1869-1877.
55. Pavese, N., Gerhard, A., Tai, Y.F., Ho, A.K., Turkheimer, F., Barker, R.A., Brooks, D.J. and Piccini, P. (2006) Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology, 66, 1638-1643.
56. Crook, Z.R. and Housman, D. (2011) Huntington's disease: can mice lead the way to treatment? Neuron, 69, 423-435.
57. Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H. et al. (2012) Neuroprotective role of Sirt1 in mammalian models of Huntington's disease through activation of multiple Sirt1 targets. Nat. Med., 18, 153-158.
58. Hult Lundh, S., Nilsson, N., Soylu, R., Kirik, D. and Petersen, A. (2013) Hypothalamic expression of mutant huntingtin contributes to the development of depressive-like behavior in the BAC transgenic mouse model of Huntington's disease. Hum. Mol. Genet., 22, 3485-3497.
59. Kudo, T., Schroeder, A., Loh, D.H., Kuljis, D., Jordan, M.C., Roos, K.P. and Colwell, C.S. (2011) Dysfunctions in circadian behavior and physiology in mouse models of Huntington's disease. Exp. Neurol., 228, 80-90.
60. Pouladi, M.A., Xie, Y., Skotte, N.H., Ehrnhoefer, D.E., Graham, R.K., Kim, J.E., Bissada, N., Yang, X.W., Paganetti, P., Friedlander, R.M. et al. (2010) Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum. Mol. Genet., 19, 1528-1538.
61. Yushkevich, P.A., Piven, J., Hazlett, H.C., Smith, R.G., Ho, S., Gee, J.C. and Gerig, G. (2006) User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage, 31, 1116-1128.